OSARTIS

Name

OSARTIS

Legal name

OSARTIS GmbH

Website

https://osartis.de

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Orthopaedic Bone Cements and Biomaterials

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle) (HLAHAEAA)

akta.pro secondary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

Keywords

• Orthopaedic bone cements
• PMMA biomaterials
• Spinal surgery products
• Bone graft substitutes
• Medical device manufacturing

Headquarters

HQ city

Munster

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. OEM/Private Label Bone Cement Manufacturing: OSARTIS develops, produces, and distributes PMMA bone cements and related accessories primarily for global orthopaedic companies under OEM/private label arrangements. These products are manufactured according to customer specifications and sold to orthopaedic industry partners.
2. Branded Product Sales: OSARTIS sells its own branded products (OSARTIS brand) directly to hospitals and hospital purchasing groups in Germany, and through trading partners internationally. This includes bone cements, mixing systems, accessories, and bone substitute materials.
3. Contract Development/Manufacturing (OEM Services): OSARTIS offers contract development and contract manufacturing services for external companies seeking custom medical device development and production capabilities.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

OSARTIS develops, manufactures, and sells PMMA bone cements (BonOs® R NF, BonOs® R NF Genta, BonOs® Inject) and synthetic bone substitute biomaterials (PerOssal®) for orthopaedic, trauma, spinal, oral, and maxillofacial surgery. The portfolio includes vacuum and manual mixing systems (EASYMIX®, ManuMix®), cement restrictors, pulse lavage systems, and vertebroplasty accessories. Products are sold directly to German hospitals, through international trading partners in 80+ countries, and as OEM/private-label supply to global orthopaedic device companies.

Product overview

OSARTIS GmbH is a medical technology company specializing in the development, manufacturing, and distribution of biomaterials and PMMA bone cements for orthopaedics, trauma surgery, spinal surgery, and oral/maxillofacial surgery. The product portfolio consists of three core categories: (1) Bone cements for endoprosthetics (BonOs® R NF, BonOs® R NF Genta) used in joint replacement with antibiotic-loaded variants for infection protection; (2) Bone cements and accessories for spinal surgery (BonOs® Inject, ManuMix®, EASYMIX® shaker) designed specifically for vertebroplasty and kyphoplasty procedures; and (3) Bone substitute materials (PerOssal®) for bone defect treatment with antibiotic-loading capability. Supporting these core products are mixing systems (EASYMIX® uno/pro/bowl/shaker), accessories including cement restrictors (C~plug®, TPA series, POLYPLUG), pulse lavage systems (PulsaClean®), and vertebroplasty accessories (VerteStable®, VERTEBROSTEEL®, VERTEBROPLASTIC®). Products are sold under the OSARTIS brand internationally via trading partners and directly in Germany to hospitals and purchasing groups. The company also offers related products from sister company Tecres S.p.A. under the Demetra Group umbrella, including preformed spacers, Cemex® bone cements, and spinal acrylic resin products. Additionally, OSARTIS provides contract development and manufacturing services (OEM) for global orthopaedic companies.

Differentiator

Problem solved

Functional benefit

Brands

• BonOs®: PMMA bone cements for joint replacement and spinal surgery applications, including BonOs® R NF, BonOs® R NF Genta, and BonOs® Inject
• EASYMIX®
• ManuMix®
• PerOssal®
• VerteStable®
• PulsaClean®
• C~plug®
• TPA / POLYPLUG

Products and services

• BonOs® R NF Fast-hardening PMMA bone cement for artificial joint replacement (arthroplasty). Formulated on Charnley principles and containing zirconium dioxide for X-ray visibility to confirm optimal cement distribution during surgery.
• BonOs® R NF Genta Antibiotic-loaded PMMA bone cement for joint replacement, containing gentamicin sulfate to protect the implant and surrounding tissue from colonization by gentamicin-sensitive pathogens while providing reliable prosthesis anchoring.
• BonOs® Inject Injectable, low-viscosity PMMA bone cement adapted for spinal surgery, suitable for fixation and filling of symptomatic vertebral compression fractures, vertebral body tumors, vertebral hemangiomas, and augmentation of pedicle screws. Contains zirconium dioxide for X-ray visibility and reduces risk of cement leakage.
• PerOssal® Synthetic, biodegradable, osteoconductive bone substitute material for filling and reconstructing bone defects. Features a microporous structure that allows uniform absorption and controlled delayed release of liquid substances including antibiotics, with full resorption and simultaneous new bone formation.
• EASYMIX® vacuum mixing systems Family of sterile vacuum mixing systems (EASYMIX® uno, EASYMIX® pro, EASYMIX® bowl, EASYMIX® shaker) for safe mixing of PMMA bone cements. Vacuum mixing reduces cement porosity, increasing strength and improving prosthesis-bone connection stability.
• ManuMix® Patented manual mixing system for low to medium viscosity bone cements with subsequent transfer to syringes via Luerlock connection. Provides homogeneous powder-liquid mixing and clean transfer for clinical use.
• PulsaClean® & PulsaClean® AC Single-use pulse lavage system combining irrigation and suction for intensive cleaning of bone or tissue defects. Suitable for both knee and hip arthroplasties, supplied with short and long attachments and femoral canal brush.
• C~plug® Resorbable distal cement restrictor that seals the intramedullary canal during implant insertion, preventing cement penetration into cancellous bone while improving cement press-fit into the implant surface. Resorbs within approximately four weeks.
• TPA / POLYPLUG cement restrictors Cement restrictors made from Ultra-High-Molecular-Weight Polyethylene (UHMWPE), available in two sizes (TPA-18 and TPA-24) to seal the femoral canal distally and prevent cement flow into the distal femoral shaft.
• VerteStable® vertebroplasty accessories Vertebroplasty accessory kit including an injector with 10ml syringe, Luer-Lock syringes (2.5ml), and cannulae with metal (VERTEBROSTEEL®) or plastic (VERTEBROPLASTIC®) handles for introducing bone cement into vertebral bodies during vertebroplasty.
• Contract Development and Manufacturing (OEM) services Contract development and contract manufacturing services for global orthopaedic companies seeking custom medical device development and production, including OEM/private-label PMMA bone cements manufactured to customer specifications under their own brand names.

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered flagship and core.

• Maxxspine Innovative GmbHflagshipStrategic or Co-development Partner · 30 April 2026Demetra, through its subsidiary OSARTIS GmbH, acquired 100% ownership of Maxxspine Innovative GmbH, a German spinal surgery solutions company founded in 2010. The acquisition strengthens Demetra's spine portfolio and reinforces presence in key European markets, with particular opportunity in kyphoplasty. OSARTIS assumes global responsibility for Maxxspine's operations and will work with the existing management team to ensure smooth integration and continuity for customers and partners.
• Tecres S.p.A.coreStrategic or Co-development Partner · 1 May 2016In May 2016, Tecres and OSARTIS co-founded Demetra Holding, creating the world's largest independent bone cement manufacturer with direct presence in Italy, USA, Germany, and China. Under Demetra's umbrella, OSARTIS operates as an independent entity while benefiting from shared resources, combined product portfolios, and international reach. The partnership enables cross-selling of products: Tecres products (spacers, Cemex® bone cements, accessories) are offered through OSARTIS channels, while OSARTIS products are available through Tecres distribution network.

Scale indicators5 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• Stryker: Stryker is a global orthopedic major that both purchases PMMA cements (potentially from OSARTIS as an OEM) and offers its own branded cements and accessories. It is the largest end-customer/competitor in arthroplasty and a key account for any specialty cement supplier.
• Smith+Nephew: Smith+Nephew is a global medical device company with a sizable orthopedics franchise (hips, knees, trauma) and is both a customer and competitor to OSARTIS in bone cements and related arthroplasty accessories.
• DePuy Synthes (Johnson & Johnson MedTech): DePuy Synthes is the orthopedic and spine arm of J&J, operating across joint reconstruction, trauma, and spine. It is a major end-market for bone cements and competes broadly with OSARTIS in arthroplasty and vertebral augmentation products.
• Enovis (DJO): Enovis (formerly DJO/Colfax) is a diversified medical device company with surgical orthopedic and extremities products. It overlaps with OSARTIS in joint reconstruction adjacencies and serves hospital customers in the same end markets.
• Zimmer Biomet: Zimmer Biomet is a top-tier global orthopedic and spine implant company that competes with OSARTIS in joint reconstruction cements and spine hardware. It is also a potential OEM/private-label customer for OSARTIS's bone cements.

Emerging players

• Exactech: Exactech is a US-based orthopedic implant company focused on extremities, knee, and hip reconstruction. It represents an emerging/specialty OEM-style player that uses third-party bone cements and competes with OSARTIS in joint reconstruction accessories.
• Medacta International: Medacta is a Swiss-based orthopedic company with a growing hip, knee, and spine franchise. It is a potential OEM customer for OSARTIS's cements and competes in adjacent arthroplasty and spine surgery segments.

Direct peers

• Teknimed: Teknimed is a France-based specialty manufacturer of PMMA bone cements, bone substitutes, and spine augmentation products, directly comparable to OSARTIS's BonOs® and PerOssal® lines. It serves a similar mix of OEM partners and branded hospital customers in Europe and internationally.
• Heraeus Medical: Heraeus Medical is the dedicated PMMA bone cement specialist behind the Palacos® brand, making it the most direct comparable to OSARTIS. Both companies focus narrowly on bone cements, mixing systems, and infection-management adjuncts for joint replacement and trauma.
• Tecres S.p.A. Tecres is OSARTIS's sister company under Demetra Holding and a direct peer in PMMA bone cements (Cemex®), antibiotic-loaded cements, and preformed spacers. The two entities share product categories, customers, and distribution geographies and compete for adjacent OEM accounts.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/osartis-gmbh

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OSARTIS